36
The company reported promising 2-year overall survival data for its RAS mutations-targeting cancer jab TG01. Targovax’ CFO Erik Wiklund presented data showing that 90% of patients with resected pancreatic cancer (29/32) had RAS-specific immune activation that led to a median survival of 33.1 months vs. 27.6 for historical control in 13 of 19 patients (68%) alive 2 years after surgery. vs. 30-53% in historical controls. in the second cohort of the trial, expected to read-out in H1/2018 13 of 13 patients (100%) were alive 1 year after surgery.
Targovax expects to start an adaptive design pivotal Phase IIb/III study in H2/2018, following…